What We Do: Building the Innovation Ecosystem
Connecting Breakthroughs to Partners, Transforming Science into Solutions
OniX strategically connects the critical pillars of therapeutic innovation. We bridge the gap between groundbreaking research—whether from universities, startups, or biotech companies—and the partners with the expertise and resources to advance these discoveries.
Our AI-powered platform identifies promising therapeutic assets across the entire innovation landscape, analyzes their potential, and facilitates precise matches between innovators and the right development partners. By bringing together academic institutions, biotech startups, pharmaceutical companies, and investors in a collaborative ecosystem, we transform the traditionally fragmented innovation process into a streamlined pathway from discovery to impact.
Where researchers create breakthrough science, and industry possesses development capabilities, OniX provides the intelligence and connections that turn scientific potential into life-changing treatments for patients worldwide.
​
OniX aggregates the Research Ecosystem
All Ideas have an impact
OniX accepts ideas from a wide spectrum of research, including: Health Sciences, Biotechnology, Medical Devices, Agriculture, Energy, Space, Transportation, Climate Change, Food and Nutrition, Farming, Fisheries, Social Sciences, Public Health, Artificial Intelligence, Software/Hardware, and others.
​
OniX harnesses the industry's most comprehensive biomedical research database, aggregating intelligence on over 1 million curated therapeutic assets and ideas. Our platform continuously tracks 160 million scientific publications, monitors 100,000+ startups across more than 50 countries, and maintains live data from 10,000+ biotech and startup pipelines. This vast repository includes extensive patent databases, clinical trial information, and real-time industry news, all enriched weekly with 5,000+ newly identified assets.
Our global network encompasses 5,000+ universities and other research organazitations and includes proprietary tracking of stealth companies and emerging technologies. By transforming this unparalleled data collection into actionable intelligence through our AI-powered analytics, OniX provides biotech innovators with the strategic insights traditionally available only to pharmaceutical giants with extensive competitive intelligence resources.
Our Technology
OniX utilizes a sophisticated AI ecosystem that combines advanced machine learning, natural language processing, and cognitive reasoning frameworks to revolutionize the discovery of novel partners, unexplored drug targets, and alternative applications for existing therapeutic candidates. Our platform orchestrates a proprietary integration of both public and private global datasets, creating an intuitive discovery hub specifically engineered for the research community.
Key Technological Features:
-
AI-Powered Analytics: Our proprietary AI algorithms process complex biomedical data relationships to identify non-obvious connections between diseases, targets, and compounds that traditional methods may overlook.
-
Advanced Machine Learning: OniX deploys state-of-the-art deep learning models trained on comprehensive biomedical datasets to predict promising drug-target interactions with remarkable precision and significantly reduced false positives.
-
Natural Language Processing (NLP): Our sophisticated NLP engines continuously extract and synthesize insights from scientific literature, clinical trial data, and regulatory documents to maintain an up-to-date knowledge repository that enhances decision-making.
-
Cognitive Reasoning Systems: OniX leverages cognitive computing to simulate expert reasoning processes, generating hypotheses and strategic recommendations based on partial information – similar to how experienced researchers approach complex problems.
-
​
The OniX Team
Founder/CEO
+25 years of experience in academia and private foundations including Columbia University College of Physicians & Surgeons, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, Hospital for Special Surgery, NYU School of Medicine, JDRF (previously Juvenile Diabetes Research Foundation), the Patient-Centered Outcomes Research Institute (PCORI) and Leidos.
-
OniX Empire Fund - Founder/CEO
-
The Lay Empowered - Founder
Previously:
-
OnPAR - Founder
-
Leidos Life Sciences - Director
-
Patient-Centered Outcomes Research Institute (PCORI) - Founder/Director
-
JDRF - COO of Research Department
-
New York University School of Medicine - Director
-
Hospital for Special Surgery - Associate Director
-
Memorial Sloan Kettering Cancer Center - Manager
-
Weil Cornell Medical College - Faculty
-
Columbia University Vagelos College of Physicians and Surgeons, Research Associate
Hadi Makki
Chief Technology Officer
Result-minded executive focused on increasing the value of the organization through rigorous strategic planning, business process engineering and effective cost management. Excels in fostering growth in business through meticulous profit & loss management, forming strategic alliances and tactical leadership. Exceptional communication and interpersonal skills, highly effective across all organizational levels.
Career Highlights
-
Transformed and set new standards for the use of Information Technology in the largest and most influential health department in the country (New York City)
-
Created and held key senior executive positions in both public and private sectors and drove business growth through strategic thinking, rigorous planning and execution, innovation and change